IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

Friday, August 29, 2025 1 min read

Key Takeaway: IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

Full Press Release Details

IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress.

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

Biotech Analyst Ratings

M&A Tracker

News

Blogs

Modality Leaderboard

Discord

User Guide

Biotech Investing 101

Recent Updates

Recently added Catalysts

Full Press Release Details